Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Schiff, R"'
Autor:
De Angelis C; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas.; Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy., Nagi C; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Hoyt CC; Akoya Biosciences, Hopkinton, Massachusetts., Liu L; Akoya Biosciences, Hopkinton, Massachusetts., Roman K; Akoya Biosciences, Hopkinton, Massachusetts., Wang C; Akoya Biosciences, Hopkinton, Massachusetts., Zheng Y; Akoya Biosciences, Hopkinton, Massachusetts., Veeraraghavan J; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas., Sethunath V; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas., Nuciforo P; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Wang T; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Tsimelzon A; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas., Mao S; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas., Hilsenbeck SG; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas., Trivedi MV; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas.; Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas., Cataldo ML; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas.; Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy., Pavlick A; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Wolff AC; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland., Weigelt B; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Prat A; Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Gutierrez C; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas., Osborne CK; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas., Rimawi MF; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas., Schiff R; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas. rschiff@bcm.edu.; Department of Medicine, Baylor College of Medicine, Houston, Texas.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Feb 01; Vol. 26 (3), pp. 738-745. Date of Electronic Publication: 2019 Oct 25.
Autor:
Rimawi MF; Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. rimawi@bcm.edu, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2013 May 10; Vol. 31 (14), pp. 1726-31. Date of Electronic Publication: 2013 Apr 08.
Autor:
Rachel Schiff, Mothaffar F. Rimawi, Matthew P. Goetz, Jorge S. Reis-Filho, Ting Wang, Britta Weigelt, Carolina Gutierrez, CK Osborne, Aleix Prat, Suzanne A. W. Fuqua, Antonio C. Wolff, R. Mao, Jamunarani Veeraraghavan, Andres Forero, Anna C. Pavlick, Paolo Nuciforo, Ingrid A. Mayer, C. De Angelis, SG Hilsenbeck, Jenny C. Chang, Ian E. Krop, Rita Nanda, Sabrina Herrera, Alejandro Contreras
Publikováno v:
Ann Oncol
BACKGROUND: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER
Autor:
Aranzazu Fernandez-Martinez, Barbara Adamo, Blanca Gonzalez-Farre, Lisa A. Carey, Francesco Schettini, Benedetta Conte, Charles M. Perou, Jamunarani Veeraraghavan, Jan C. Brase, Sabino De Placido, Tomás Pascual, Mariavittoria Locci, Pierfranco Conte, Patricia Villagrasa, Montserrat Muñoz, Sonia Pernas, Fara Brasó-Maristany, Olga Martínez, Patricia Galván, Maria Vidal, Mothaffar F. Rimawi, C. Kent Osborne, Carla Rognoni, Gaia Griguolo, Rachel Schiff, Nuria Chic, Valentina Guarneri, Aleix Prat
Publikováno v:
Cancer Treat Rev
Background: HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be associated with higher pathological complete response (pCR) rates following anti-HER2-based reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456360a8625da925d93580bf31f87b0f
https://europepmc.org/articles/PMC7230134/
https://europepmc.org/articles/PMC7230134/
Autor:
Britta Weigelt, Anne Pavlick, C. Kent Osborne, Marilyn M. Li, Kathleen A. Burke, Jorge S. Reis-Filho, Tao Wang, Fresia Pareja, Matthew P. Goetz, Rachel Schiff, Jenny C. Chang, Rita Nanda, Suzanne A. W. Fuqua, Carmine De Angelis, Ian E. Krop, Ingrid A. Mayer, Mothaffar F. Rimawi, Sabrina Herrera, Antonio C. Wolff, Andres Forero, Felipe C Geyer, Alejandro Contreras, Susan G. Hilsenbeck, Carolina Gutierrez
Publikováno v:
Breast Cancer Research and Treatment. 167:731-740
Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in
Autor:
Sabrina Herrera, Meghana V. Trivedi, Sufeng Mao, Mario Giuliano, Joe W. Gray, Carmine De Angelis, Sara López-Tarruella, Huizhong Hu, Laura M. Heiser, Yen-Chao Wang, C. Kent Osborne, Rachel Schiff, Nicholas J. Wang, Mothaffar F. Rimawi, Anne Pavlick, Agostina Nardone, Jenny C. Chang, Alejandro Contreras, Susan G. Hilsenbeck, Gary C. Chamness, Xiaoyong Fu, Tao Wang, Carolina Gutierrez
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Purpose: To investigate the direct effect and therapeutic consequences of epidermal growth factor receptor 2 (HER2)-targeting therapy on expression of estrogen receptor (ER) and Bcl2 in preclinical models and clinical tumor samples. Experimental desi